Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
4
×
Tags
boston blog main
boston top stories
life sciences
national blog main
national top stories
new york blog main
4
×
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
biotech
bristol-myers squibb
intercept pharmaceuticals
boulder/denver blog main
boulder/denver top stories
celgene
clinical trials
deals
detroit blog main
detroit top stories
genentech
indiana blog main
indiana top stories
liver
liver disease
nash
national
nonalcoholic steatohepatitis
obeticholic acid
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
2019
What
liver
4
×
disease
drug
approved
bio
fatty
known
nash
new
race
roundup
advanced
aiming
alnylam’s
ambys
approval
bff
big
biotech
companies
conference
control
data
deadly
deal
deals
debuted
devoted
digital
diseases
easl
epidemic
fda
form
formed
frenzied
future
gene
growing
horizon
Language
Current search:
liver
×
photo
×
" new york blog main "
×
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?